title: Single injection of CD34+ progenitor-derived dendritic cell vaccine can lead to induction of T-cell immunity in patients with stage IV melanoma.
abstract: There is evidence that dendritic cell (DC) vaccines induce tumor-specific immune responses that correlate with clinical responses. Little is known, however, about the kinetics of T-cell responses to antigens presented on DC vaccines. The authors vaccinated 18 HLA A*0201+ patients with stage IV melanoma with CD34 HPC-derived DCs pulsed with six antigens: influenza matrix peptide (Flu-MP), KLH, and peptides derived from the four melanoma antigens: MART-1/Melan A, gp100, tyrosinase, and MAGE-3. A single DC vaccination was sufficient for induction of KLH-specific CD4 T-cell responses in five patients and Flu-MP-specific CD8 T-cell responses in eight patients. A single DC vaccine was sufficient for induction of tumor-specific effectors to at least one melanoma antigen in five patients. Thus, a single injection of CD34 HPC-derived DCs can lead to rapid immune response to CD4 epitopes or to melanoma antigens.
authors.affiliation: Baylor Institute for Immunology Research, 3434 Live Oak, Dallas, Texas 75204, USA. karolinp@baylorhealth.edu
authors.forename: A Karolina
authors.initials: AK
authors.lastname: Palucka
authors.forename: Madhav V
authors.initials: MV
authors.lastname: Dhodapkar
authors.forename: Sophie
authors.initials: S
authors.lastname: Paczesny
authors.forename: Susan
authors.initials: S
authors.lastname: Burkeholder
authors.forename: Knut M
authors.initials: KM
authors.lastname: Wittkowski
authors.forename: Ralph M
authors.initials: RM
authors.lastname: Steinman
authors.forename: Joseph
authors.initials: J
authors.lastname: Fay
authors.forename: Jacques
authors.initials: J
authors.lastname: Banchereau
mesh_terms: D000293:Adolescent; D000328:Adult; D018952:Antigens, CD34 / Q000276:immunology*; D000951:Antigens, Neoplasm / Q000276:immunology*; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology*; D019496:Cancer Vaccines / Q000008:administration & dosage / Q000276:immunology / Q000627:therapeutic use*; D003602:Cytotoxicity, Immunologic; D003713:Dendritic Cells / Q000276:immunology*; D015789:HLA-A2 Antigen / Q000276:immunology; D006801:Humans; D016219:Immunotherapy, Adoptive / Q000379:methods; D008213:Lymphocyte Activation; D008545:Melanoma / Q000276:immunology* / Q000628:therapy*; D014442:Monophenol Monooxygenase / Q000378:metabolism; D009367:Neoplasm Staging
chemical_list: D018952:Antigens, CD34; D000951:Antigens, Neoplasm; D019496:Cancer Vaccines; D015789:HLA-A2 Antigen; D014442:Monophenol Monooxygenase